Sandra Gofinet Pasoto

Sandra Gofinet Pasoto

Auto-generated profile, based on publicly available information

Sandra Gofinet Pasoto

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Open Access Rheumatology: Research and Reviews
Verified
Journal Article
Open access
PDF file
SPSandra Gofinet Pasoto
Sandra Gofinet Pasoto
VMVictor Adriano de Oliveira Martins
Victor Adriano de Oliveira Martins
EBEloisa Bonfa
Eloisa Bonfa
Systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS) may coexist, and they are chronic complex disorders, with an autoimmune background, multifactorial etiology, multiple circulating autoantibodies, and variable prognosis. The prominent feature of SS is the impairment of the lacrimal and salivary glands leading to sicca symptoms. This disease may be classified as primary Sjögren’s syndrome (pSS), or secondary Sjögren’s syndrome (sSS) since it is often associated to other autoimmune disorders, principally SLE, rheumatoid arthritis, and systemic sclerosis. Systematic reviews and meta-analyses show an sSS prevalence in SLE patients of about 14%–17.8%. Herein, we updated important aspects of the clinical association between SLE and sSS through a narrative review of the PubMed database in the last 5 years (from July 2013 to October 2018) with the terms “Sjogren syndrome and systemic lupus erythematosus”. The following aspects are addressed: the classification criteria for sSS; differences and similarities between SLE and pSS regarding demographic, clinical, and serological characteristics (including new autoantibodies), as well as comorbidities; the etiopathogenic links between SLE and pSS (including genetic and environmental factors, B-cell activation, and autoantibodies); the predictive factors for sSS onset in SLE patients; the ocular and oral involvements due to sSS in SLE; and the main distinctive demographic, clinical, and serological features of SLE with and without associated SS.

14 September 2015 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
KAKristopherson Lustosa Augusto
Kristopherson Lustosa Augusto
EBEloisa Bonfa
Eloisa Bonfa
RPRosa Maria L.N. Pereira
Rosa Maria L.N. Pereira
CBCleonice Bueno
Cleonice Bueno
ELElaine Pires Leon
Elaine Pires Leon
SPSandra Gofinet Pasoto
Sandra Gofinet Pasoto

20 May 2022 in Lupus
Verified
Journal Article
Open access
FSFlavio Signorelli
Flavio Signorelli
GBGustavo Guimarães Moreira Balbi
Gustavo Guimarães Moreira Balbi
NANadia E Aikawa
Nadia E Aikawa
CSClovis A Silva
Clovis A Silva
LKLéonard de Vinci Kanda Kupa
Léonard de Vinci Kanda Kupa
EBEloisa Bonfá
Eloisa Bonfá
Objective: Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). Recent reports of thrombosis associated with adenovirus-based vaccines raised concern that SARS-CoV-2 immunization in primary antiphospholipid syndrome (PAPS) patients may trigger clotting complications. Our objectives were to assess immunogenicity, safety, and aPL production in PAPS patients, after vaccinating with Sinovac-CoronaVac, an inactivated virus vaccine against COVID-19. Methods: This prospective controlled phase-4 study of PAPS patients and a control group (CG) consisted of a two-dose Sinovac-CoronaVac (D0/D28) and blood collection before vaccination (D0), at D28 and 6 weeks after second dose (D69) for immunogenicity/aPL levels. Outcomes were seroconversion (SC) rates of anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies (NAb) at D28/D69 in naïve participants. Safety and aPL production were also assessed. Results: We included 44 PAPS patients (31 naïve) and 132 CG (108 naïve) with comparable age ( p=0.982) and sex ( p>0.999). At D69, both groups had high and comparable SC (83.9% vs. 93.5%, p=0.092), as well as NAb positivity (77.4% vs. 78.7%, p=0.440), and NAb-activity (64.3% vs. 60.9%, p=0.689). Thrombotic events up to 6 months or other moderate/severe side effects were not observed. PAPS patients remained with stable aPL levels throughout the study at D0 vs. D28 vs. D69: anticardiolipin (aCL) IgG ( p=0.058) and IgM ( p=0.091); anti-beta-2 glycoprotein I (aβ2GPI) IgG ( p=0.513) and IgM ( p=0.468). Conclusion: We provided novel evidence that Sinovac-CoronaVac has high immunogenicity and safety profile in PAPS. Furthermore, Sinovac-CoronaVac did not trigger thrombosis nor induced changes in aPL production.

19 February 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
LGL. K. N. Guedes
L. K. N. Guedes
ELE. P. Leon
E. P. Leon
TBT. S. Bocate
T. S. Bocate
KBK. R. Bonfigliolli
K. R. Bonfigliolli
SLS. V. Lourenço
S. V. Lourenço
SPS. G. Pasoto
S. G. Pasoto

1 June 2022 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
VTVirginia Fernandes Moça Trevisani
Virginia Fernandes Moça Trevisani
APAlisson Pugliesi
Alisson Pugliesi
SPSandra Gofinet Pasoto
Sandra Gofinet Pasoto
MLMaria Lucia Lemos Lopes
Maria Lucia Lemos Lopes
LGLissiane Noronha Guedes
Lissiane Noronha Guedes
VVValeria Valim
Valeria Valim
Sjogren's Syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and other organs, associated with sicca syndrome but also with systemic involvement with varying degrees of severity. Despite their importance, these systemic manifestations are not routinely evaluated and there is no homogenous approach to their diagnosis or evaluation. To close this gap, a panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis on the identification of epidemiologic and clinical features of these manifestations and made recommendations based on the findings. Agreement between the experts was achieved using the Delphi method. The first part of this guideline summarizes the most important topics, and 11 recommendations are provided for the articular, pulmonary, and renal care of SS patients.

29 November 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ATAdriana Coracini Tonacio
Adriana Coracini Tonacio
TPTatiana Do Nascimento Pedrosa
Tatiana Do Nascimento Pedrosa
EBEduardo Ferreira Borba
Eduardo Ferreira Borba
NANadia Emi Aikawa
Nadia Emi Aikawa
SPSandra Gofinet Pasoto
Sandra Gofinet Pasoto
EBEloisa Bonfá
Eloisa Bonfá
Background: Brazil faced a yellow fever(YF) outbreak in 2016–2018 and vaccination was considered for autoimmune rheumatic disease patients(ARD) with low immunosuppression due to YF high mortality. Objective: This study aimed to evaluate, prospectively for the first time, the short-term immunogenicity of the fractional YF vaccine(YFV) immunization in ARD patients with low immunossupression. Methods and Results: A total of 318 participants(159 ARD and 159 age- and sex-matched healthy controls) were vaccinated with the fractional-dose(one fifth) of 17DD-YFV. All subjects were evaluated at entry(D0), D5, D10, and D30 post-vaccination for clinical/laboratory and disease activity parameters for ARD patients. Post-vaccination seroconversion rate(83.7%vs.96.6%, p = 0.0006) and geometric mean titers(GMT) of neutralizing antibodies[1143.7 (95%CI 1012.3–1292.2) vs.731 (95%CI 593.6–900.2), p0.05). Conclusion: Fractional-dose 17DD-YF vaccine in ARD patients resulted in a high rate of seroconversion rate(>80%) but lower than controls, with a longer but less intense viremia. This vaccine was immunogenic, safe and did not induce flares in ARD under low immunosuppression and may be indicated in YF outbreak situations and for patients who live or travel to endemic areas. Trial registration: This clinical trial was registered with Clinicaltrials.gov (#NCT03430388).